For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Alx Oncology Holdings Inc (NASDAQ: ALXO) closed at $15.74 in the last session, down -2.11% from day before closing price of $16.08. In other words, the price has decreased by -$2.11 from its previous closing price. On the day, 0.67 million shares were traded. ALXO stock price reached its highest trading level at $16.1475 during the session, while it also had its lowest trading level at $15.08.
Ratios:
We take a closer look at ALXO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.24 and its Current Ratio is at 5.24. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Stifel on March 08, 2024, Downgraded its rating to Hold and sets its target price to $14 from $10 previously.
On December 08, 2023, Jefferies Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $8 to $18.
Jefferies Downgraded its Buy to Hold on December 22, 2021, whereas the target price for the stock was revised from $65 to $25.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 16 ’24 when Pons Jaume sold 50,000 shares for $14.20 per share. The transaction valued at 710,195 led to the insider holds 604,205 shares of the business.
Pons Jaume sold 20,000 shares of ALXO for $223,036 on Apr 04 ’24. The PRESIDENT & CSO now owns 628,359 shares after completing the transaction at $11.15 per share. On Mar 14 ’24, another insider, Lettmann Jason, who serves as the CHIEF EXECUTIVE OFFICER of the company, bought 4,400 shares for $11.31 each. As a result, the insider paid 49,771 and bolstered with 171,620 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALXO now has a Market Capitalization of 789394048 and an Enterprise Value of 623854784.
Stock Price History:
Over the past 52 weeks, ALXO has reached a high of $17.42, while it has fallen to a 52-week low of $3.94. The 50-Day Moving Average of the stock is 15.82%, while the 200-Day Moving Average is calculated to be 60.72%.
Shares Statistics:
According to the various share statistics, ALXO traded on average about 450.23K shares per day over the past 3-months and 823050 shares per day over the past 10 days. A total of 49.95M shares are outstanding, with a floating share count of 27.36M. Insiders hold about 45.44% of the company’s shares, while institutions hold 57.80% stake in the company. Shares short for ALXO as of 1711584000 were 3120969 with a Short Ratio of 6.93, compared to 1709164800 on 3477694. Therefore, it implies a Short% of Shares Outstanding of 3120969 and a Short% of Float of 12.7.
Earnings Estimates
The current rating of Alx Oncology Holdings Inc (ALXO) is the result of assessments by Alto Ingredients, Inc. analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $12.89, with high estimates of $15.74 and low estimates of $3.46.
Analysts are recommending an EPS of between $Healthcare and $Healthcare for the fiscal current year, implying an average EPS of $Healthcare.
